Comparing the current results to its competitors, Xoma Royalty reported Revenue decrease in the 1 quarter 2026 year on year by -22.59 %, despite the revenue increase by the most of its competitors of 12.72 %, recorded in the same quarter.
Xoma Royalty Corporation Net Income in the 1 quarter 2026 grew year on year by 200.85%, while most of its competitors have experienced a contraction in net income by -30.59 %.
Xoma Royalty's Comment on Competition and Industry Peers
The biotechnology and pharmaceutical industries are undergoing significant technological changes, with competition arising from drugs developed by licensees or milestone and royalty partners that may compete with existing therapies or other product candidates. Academic institutions, government agencies, and other organizations may seek patent protection for competing products or technologies and collaborate with competitors. The development of generics or biosimilars may render licensees' or royalty partners' products obsolete or uncompetitive. The company's royalty aggregator model competes with other companies, funds, and investment vehicles that aggregate royalties or provide alternative financing to development-stage biotechnology and pharmaceutical companies. These competitors may have lower target rates of return, lower costs of capital, or greater access to capital, enabling them to acquire assets targeted by the company. Additionally, large pharmaceutical companies, as existing or potential competitors to the company's partners and licensees, may possess greater financial, technical, and human resources, enabling them to develop, manufacture, and market products with extensive experience in preclinical studies, clinical trials, regulatory approvals, and marketing.
April 14, 2025
In a dynamic landscape dominated by relentless competition, XOMA Royalty Corporation has made notable strides with the recent divestiture of its remaining Kinnate pipeline assets. This strategic move has potentially transformative implications for the company, with total proceeds from the sale reaching as high as $270 million. The deal encompasses not only upfront and milestone payments but also royalties from future commercial sales, which are projected to range from low single digits to mid-teens a financial framework that underscores XOMA s ongoing strategic alignment in the biotech sector.The fourth quarter of 2024 proved to be a landmark period for XOMA, as the company reported an astonishing revenue in...
May 9, 2024
In the first quarter of 2024, biotech company XOMA Corporation reported robust financial results and announced the U.S. Food and Drug Administration’s (FDA) approval of Day One s medical breakthrough OJEMDA (tovorafenib). This significant development has precipitated the receipt of a $9 million milestone for XOMA and opens up an additional reve...
April 25, 2024
brings you the latest development in the field of oncology, as XOMA Pharmaceuticals celebrates a significant milestone. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Day One Biopharmaceuticals OJEMDATM (tovorafenib) for the treatment of relapsed or refractory BRAF-altered Pedi...
Legend Biotech Corporation is a biotech company focused on developing innovative cell therapies and gene therapies to address unmet medical needs in various diseases.
HCW Biologics Inc is a biotechnology company that operates on a business model focused on the research, development, and commercialization of biologic therapies. The company primarily focuses on developing and manufacturing novel biological products for various medical conditions. Their business model involves collaboration with industry partners, conducting clinical trials, and securing regulatory approvals for the commercialization of their biologic therapies.
Hutchmed China Limited operates on a vertically integrated platform, focusing on the discovery, development, and commercialization of targeted therapeutics for oncology and immunological diseases. The company employs a comprehensive business model that encompasses research and development, manufacturing, marketing, and sales in order to deliver innovative drugs to patients. By leveraging its internal capabilities and strategic partnerships, Hutchmed China aims to transform the treatment landscape and improve the lives of patients in China and around the world.
Grifols SA operates a business model that focuses on plasma-derived medicine production and commercialization, including plasma collection, testing, and fractionation, as well as the development of diagnostic equipment and transfusion medicine. Their core activities involve the extraction of plasma, transforming it into life-saving therapies, and distributing them worldwide to healthcare providers.
Sources:
Xoma Royalty Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Xoma Royalty Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
